ONCTERNAL THERAPEUTICS INC
ONCTERNAL THERAPEUTICS INC logo
ONCT

ONCTERNAL THERAPEUTICS INC (ONCT)

$0.91013.15%

Market is closed
– opens on 8 PM, 01 Dec 2022
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$0.9
Day's Range
$0.972999
$0.6902
52-Week Range
$3.08
1 month return13.32%
3 month return18.74%
1 year return67.5%
5 year return93.0%

Company Information

Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer generation or progression. The clinical pipeline includes cirmtuzumab, an investigational monoclonal antibody designed to inhibit the ROR1 pathway, a type I tyrosine kinase-like orphan receptor, that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) and in an investigator-sponsored, Phase 1b clinical trial in combination with paclitaxel for the treatment of women with HER2-negative metastatic or locally advanced, unresectable breast cancer. The clinical pipeline also includes TK216, an investigational targeted small-molecule inhibitor of the ETS family of oncoproteins, that is being evaluated in a Phase 1 clinical trial for patients with Ewing sarcoma alone and in combination with vincristine chemotherapy. In addition, Oncternal has a program utilizing the cirmtuzumab antibody backbone to develop a CAR-T therapy that targets ROR1, which is currently in preclinical development as a potential treatment for hematologic cancers and solid tumors.
OrganizationONCTERNAL THERAPEUTICS INC
Employees26
CEODr. James B. Breitmeyer M.D., Ph.D.
IndustryBiotechnology

Analyst Recommendation

based on 4 analysts ratings

Buy
100%
Buy
0%
Hold
0%
Sell

Based on 4 Wall street analysts offering stock ratings for ONCTERNAL THERAPEUTICS INC(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 877.91%

Current

$0.91

Target

$8.9

Recommendation Trend

Based on 4 analyst

Current1M Ago3M Ago
Buy
4
11
11
Hold
0
1
1
Sell
0
0
0
Consensus
BUY
BUY
BUY

Highlights

Market Capitalization
52.9M
Book Value
$1.24
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-0.71
Wall Street Target Price
8.9

Valuation

Trailing PE0.0
Forward PE0.0
Price/Book (mrq)
0.79
Enterprise Value
-16478796
Enterprise Value/Revenue
0.85
Enterprise Value/Ebitda
0.4

Technicals

Beta
1.44
50 Day MA
0.98
200 Day MA
1.17

Institutional Holdings

Vanguard Group Inc

5.08%

Millennium Management LLC

2.3%

Citadel Advisors Llc

2.06%

Renaissance Technologies Corp

1.14%

Geode Capital Management, LLC

0.73%

Brighton Jones LLC

0.59%

Discover more

Frequently Asked Questions

What is ONCTERNAL THERAPEUTICS INC share price today?

Can Indians buy ONCTERNAL THERAPEUTICS INC shares?

How can I buy ONCTERNAL THERAPEUTICS INC shares from India?

Can Fractional shares of ONCTERNAL THERAPEUTICS INC be purchased?

What are the documents required to start investing in ONCTERNAL THERAPEUTICS INC stocks?

What are today’s High and Low prices of ONCTERNAL THERAPEUTICS INC?

What are today’s traded volumes of ONCTERNAL THERAPEUTICS INC?

What is today’s market capitalisation of ONCTERNAL THERAPEUTICS INC?

What is the 52 Week High and Low Range of ONCTERNAL THERAPEUTICS INC?

How much percentage ONCTERNAL THERAPEUTICS INC is down from its 52 Week High?

How much percentage ONCTERNAL THERAPEUTICS INC is up from its 52 Week low?

What are the historical returns of ONCTERNAL THERAPEUTICS INC?

Who is the Chief Executive Officer (CEO) of ONCTERNAL THERAPEUTICS INC?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*